JP2008534534A - Ｍｍｐ阻害剤としての置換テトラヒドロイソキノリン、関連する製造法及び医薬としての使用 - Google Patents
Ｍｍｐ阻害剤としての置換テトラヒドロイソキノリン、関連する製造法及び医薬としての使用 Download PDFInfo
- Publication number
- JP2008534534A JP2008534534A JP2008503400A JP2008503400A JP2008534534A JP 2008534534 A JP2008534534 A JP 2008534534A JP 2008503400 A JP2008503400 A JP 2008503400A JP 2008503400 A JP2008503400 A JP 2008503400A JP 2008534534 A JP2008534534 A JP 2008534534A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- group
- alkylene
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 229940124761 MMP inhibitor Drugs 0.000 title description 4
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 121
- 239000000126 substance Substances 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 142
- 125000002947 alkylene group Chemical group 0.000 claims description 70
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 52
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 51
- -1 NR 8 R 9 Chemical group 0.000 claims description 45
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 44
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 38
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 23
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000006413 ring segment Chemical group 0.000 claims description 18
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 12
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 150000003456 sulfonamides Chemical class 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 125000004193 piperazinyl group Chemical class 0.000 claims description 7
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000002757 morpholinyl group Chemical class 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical class 0.000 claims description 6
- 229940124530 sulfonamide Drugs 0.000 claims description 6
- 208000012659 Joint disease Diseases 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 125000002883 imidazolyl group Chemical class 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 125000003386 piperidinyl group Chemical class 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical class 0.000 claims description 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 3
- 206010002388 Angina unstable Diseases 0.000 claims description 3
- 208000036487 Arthropathies Diseases 0.000 claims description 3
- 208000017667 Chronic Disease Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010061216 Infarction Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims description 3
- 208000007814 Unstable Angina Diseases 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 125000005604 azodicarboxylate group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 238000005886 esterification reaction Methods 0.000 claims description 3
- 230000007574 infarction Effects 0.000 claims description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000005801 spondylosis Diseases 0.000 claims description 3
- 150000003573 thiols Chemical class 0.000 claims description 3
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 208000026816 acute arthritis Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000008355 cartilage degradation Effects 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 208000018631 connective tissue disease Diseases 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 210000003041 ligament Anatomy 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 210000004417 patella Anatomy 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 230000036262 stenosis Effects 0.000 claims description 2
- 208000037804 stenosis Diseases 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 230000017423 tissue regeneration Effects 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000036269 ulceration Effects 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000004097 bone metabolism Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 239000011159 matrix material Substances 0.000 abstract description 6
- 102000005741 Metalloproteases Human genes 0.000 abstract description 4
- 108010006035 Metalloproteases Proteins 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 29
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 19
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 16
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- OXFGRWIKQDSSLY-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-2-ium-1-carboxylate Chemical compound C1=CC=C2C(C(=O)O)NCCC2=C1 OXFGRWIKQDSSLY-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 238000010626 work up procedure Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 0 *CCCS(N(CCc1c2)C(C(O)=O)c1ccc2O**)(=O)=O Chemical compound *CCCS(N(CCc1c2)C(C(O)=O)c1ccc2O**)(=O)=O 0.000 description 4
- FLGVKOCPVIQILN-UHFFFAOYSA-N 2-(4-fluorophenoxy)benzenesulfonyl chloride Chemical compound C1=CC(F)=CC=C1OC1=CC=CC=C1S(Cl)(=O)=O FLGVKOCPVIQILN-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 3
- KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 3
- DLYIRDWZHUHDTB-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-6-(2-imidazol-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=CC=1OCCN1C=CN=C1 DLYIRDWZHUHDTB-UHFFFAOYSA-N 0.000 description 3
- VHXXSBPJAHQNLX-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-6-[3-(4-methylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1CN(C)CCN1CCCOC1=CC=C(C(N(CC2)S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)C(O)=O)C2=C1 VHXXSBPJAHQNLX-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- HWSMEOSRHAZBOT-UHFFFAOYSA-N 6-(2-imidazol-1-ylethoxy)-2-[4-(4-methoxyphenoxy)phenyl]sulfonyl-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(S(=O)(=O)N2C(C3=CC=C(OCCN4C=NC=C4)C=C3CC2)C(O)=O)C=C1 HWSMEOSRHAZBOT-UHFFFAOYSA-N 0.000 description 3
- KEBRWLCRHHVGDC-UHFFFAOYSA-N 6-[2-(diethylamino)ethoxy]-2-[4-(4-fluorophenoxy)phenyl]sulfonyl-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1CC2=CC(OCCN(CC)CC)=CC=C2C(C(O)=O)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 KEBRWLCRHHVGDC-UHFFFAOYSA-N 0.000 description 3
- HQKRREVRLDRQMN-UHFFFAOYSA-N 8-bromo-2-[4-(4-fluorophenoxy)phenyl]sulfonyl-5-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1=CC(Br)=C2C(C(=O)O)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=C1OCCN1CCCCC1 HQKRREVRLDRQMN-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000002148 esters Chemical group 0.000 description 3
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- WSWPCNMLEVZGSM-UHFFFAOYSA-N 2-(2-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC=C1CCN WSWPCNMLEVZGSM-UHFFFAOYSA-N 0.000 description 2
- SLUPHEJCXJOSCF-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonyl-5-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C(C(O)=O)C2=CC=CC(OCCN3CCCCC3)=C2CC1 SLUPHEJCXJOSCF-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- PUHMDAKRJNLUEL-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-5-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=C1OCCN1CCCCC1 PUHMDAKRJNLUEL-UHFFFAOYSA-N 0.000 description 2
- OBUSCRVUNJDSHD-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-6-(2-methoxyethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1CC2=CC(OCCOC)=CC=C2C(C(O)=O)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 OBUSCRVUNJDSHD-UHFFFAOYSA-N 0.000 description 2
- RQQCLAWKPJEETG-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-6-(2-morpholin-4-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=CC=1OCCN1CCOCC1 RQQCLAWKPJEETG-UHFFFAOYSA-N 0.000 description 2
- ZLQGNIHELZKTEQ-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-6-(2-morpholin-4-ylethoxy)-n-(oxan-2-yloxy)-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C1=CC(F)=CC=C1OC1=CC=C(S(=O)(=O)N2C(C3=CC=C(OCCN4CCOCC4)C=C3CC2)C(=O)NOC2OCCCC2)C=C1 ZLQGNIHELZKTEQ-UHFFFAOYSA-N 0.000 description 2
- SQTYIPJPYKZZNX-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-6-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=CC=1OCCN1CCCCC1 SQTYIPJPYKZZNX-UHFFFAOYSA-N 0.000 description 2
- NIHFXWZDAUIWBK-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-n-hydroxy-5-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C1=CC=C2C(C(=O)NO)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=C1OCCN1CCCCC1 NIHFXWZDAUIWBK-UHFFFAOYSA-N 0.000 description 2
- STRMIWKURJFJNK-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-n-hydroxy-6-(2-imidazol-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C=1C=C2C(C(=O)NO)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=CC=1OCCN1C=CN=C1 STRMIWKURJFJNK-UHFFFAOYSA-N 0.000 description 2
- UBIVNXSILBQWCT-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-n-hydroxy-6-(2-methoxyethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C1CC2=CC(OCCOC)=CC=C2C(C(=O)NO)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 UBIVNXSILBQWCT-UHFFFAOYSA-N 0.000 description 2
- XXGWGMQOBDLJKN-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-n-hydroxy-6-(2-morpholin-4-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C=1C=C2C(C(=O)NO)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=CC=1OCCN1CCOCC1 XXGWGMQOBDLJKN-UHFFFAOYSA-N 0.000 description 2
- PZTIFNABAUBXFO-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-n-hydroxy-6-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C=1C=C2C(C(=O)NO)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=CC=1OCCN1CCCCC1 PZTIFNABAUBXFO-UHFFFAOYSA-N 0.000 description 2
- KKTFJRZCFYBOIH-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-n-hydroxy-6-[3-(4-methylpiperazin-1-yl)propoxy]-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C1CN(C)CCN1CCCOC1=CC=C(C(N(CC2)S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)C(=O)NO)C2=C1 KKTFJRZCFYBOIH-UHFFFAOYSA-N 0.000 description 2
- HTCYHWHXOYEIBY-UHFFFAOYSA-N 2-[4-(4-methoxyphenoxy)phenyl]sulfonyl-6-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(S(=O)(=O)N2C(C3=CC=C(OCCN4CCCCC4)C=C3CC2)C(O)=O)C=C1 HTCYHWHXOYEIBY-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 2
- AMSDWLOANMAILF-UHFFFAOYSA-N 2-imidazol-1-ylethanol Chemical compound OCCN1C=CN=C1 AMSDWLOANMAILF-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- SGIDPBBGJLZCLT-UHFFFAOYSA-N 4-(4-fluorophenoxy)-n-[2-(2-hydroxyphenyl)ethyl]benzenesulfonamide Chemical compound OC1=CC=CC=C1CCNS(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 SGIDPBBGJLZCLT-UHFFFAOYSA-N 0.000 description 2
- MGQWSOVAUUJYNO-UHFFFAOYSA-N 4-(4-fluorophenoxy)-n-[2-(2-methoxyphenyl)ethyl]benzenesulfonamide Chemical compound COC1=CC=CC=C1CCNS(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 MGQWSOVAUUJYNO-UHFFFAOYSA-N 0.000 description 2
- OBUBGLXGXJNQIF-UHFFFAOYSA-N 4-(4-fluorophenoxy)-n-[2-[2-(2-piperidin-1-ylethoxy)phenyl]ethyl]benzenesulfonamide Chemical compound C1=CC(F)=CC=C1OC1=CC=C(S(=O)(=O)NCCC=2C(=CC=CC=2)OCCN2CCCCC2)C=C1 OBUBGLXGXJNQIF-UHFFFAOYSA-N 0.000 description 2
- HDIKIJUPJYLXDH-UHFFFAOYSA-N 4-(4-methoxyphenoxy)benzenesulfonyl chloride Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(S(Cl)(=O)=O)C=C1 HDIKIJUPJYLXDH-UHFFFAOYSA-N 0.000 description 2
- SVTHWNXXMXEREN-UHFFFAOYSA-N 4-methyl-n-[2-[2-(2-piperidin-1-ylethoxy)phenyl]ethyl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCCC1=CC=CC=C1OCCN1CCCCC1 SVTHWNXXMXEREN-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- SUJANKHRGIKZHD-UHFFFAOYSA-N 6-[2-(diethylamino)ethoxy]-2-[4-(4-fluorophenoxy)phenyl]sulfonyl-n-hydroxy-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C1CC2=CC(OCCN(CC)CC)=CC=C2C(C(=O)NO)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 SUJANKHRGIKZHD-UHFFFAOYSA-N 0.000 description 2
- VZGMTZOASFLATH-UHFFFAOYSA-N 6-[2-(diethylamino)ethoxy]-2-[4-(4-methoxyphenoxy)phenyl]sulfonyl-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1CC2=CC(OCCN(CC)CC)=CC=C2C(C(O)=O)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(OC)C=C1 VZGMTZOASFLATH-UHFFFAOYSA-N 0.000 description 2
- ZHBCTHVPWLYAPX-UHFFFAOYSA-N 6-[2-(diethylamino)ethoxy]-n-hydroxy-2-[4-(4-methoxyphenoxy)phenyl]sulfonyl-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C1CC2=CC(OCCN(CC)CC)=CC=C2C(C(=O)NO)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(OC)C=C1 ZHBCTHVPWLYAPX-UHFFFAOYSA-N 0.000 description 2
- IIBGSJRJRAZMNF-UHFFFAOYSA-N 8-bromo-2-[4-(4-fluorophenoxy)phenyl]sulfonyl-5-hydroxy-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1CC2=C(O)C=CC(Br)=C2C(C(=O)O)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 IIBGSJRJRAZMNF-UHFFFAOYSA-N 0.000 description 2
- HHIVUAYDDMOIAC-UHFFFAOYSA-N 8-bromo-2-[4-(4-fluorophenoxy)phenyl]sulfonyl-5-methoxy-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1CC=2C(OC)=CC=C(Br)C=2C(C(O)=O)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 HHIVUAYDDMOIAC-UHFFFAOYSA-N 0.000 description 2
- BPVUQLMTZKSJPJ-UHFFFAOYSA-N 8-bromo-2-[4-(4-fluorophenoxy)phenyl]sulfonyl-n-hydroxy-5-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C1=CC(Br)=C2C(C(=O)NO)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=C1OCCN1CCCCC1 BPVUQLMTZKSJPJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N anhydrous trimethylamine Natural products CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 2
- UYKVSJYMKQPONE-UHFFFAOYSA-N ethyl 6-hydroxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylate Chemical compound OC1=CC=C2C(C(=O)OCC)NCCC2=C1 UYKVSJYMKQPONE-UHFFFAOYSA-N 0.000 description 2
- PUYLXEMTBMKMQS-UHFFFAOYSA-N ethyl 8-bromo-2-[4-(4-fluorophenoxy)phenyl]sulfonyl-5-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C1=CC(Br)=C2C(C(=O)OCC)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=C1OCCN1CCCCC1 PUYLXEMTBMKMQS-UHFFFAOYSA-N 0.000 description 2
- SYWYTYOYOJZPDH-UHFFFAOYSA-N ethyl 8-bromo-2-[4-(4-fluorophenoxy)phenyl]sulfonyl-5-hydroxy-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C1CC2=C(O)C=CC(Br)=C2C(C(=O)OCC)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 SYWYTYOYOJZPDH-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000005980 hexynyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- CZXRAUYQZAAZPW-UHFFFAOYSA-N methyl 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-6-(2-imidazol-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C=1C=C2C(C(=O)OC)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=CC=1OCCN1C=CN=C1 CZXRAUYQZAAZPW-UHFFFAOYSA-N 0.000 description 2
- IDYHBTVVOFPIAJ-UHFFFAOYSA-N methyl 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-6-(2-methoxyethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C1CC2=CC(OCCOC)=CC=C2C(C(=O)OC)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 IDYHBTVVOFPIAJ-UHFFFAOYSA-N 0.000 description 2
- LARZRKOTHZNCKC-UHFFFAOYSA-N methyl 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-6-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C=1C=C2C(C(=O)OC)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=CC=1OCCN1CCCCC1 LARZRKOTHZNCKC-UHFFFAOYSA-N 0.000 description 2
- DZEMPVYLCREZSC-UHFFFAOYSA-N methyl 2-[4-(4-methoxyphenoxy)phenyl]sulfonyl-6-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C=1C=C2C(C(=O)OC)N(S(=O)(=O)C=3C=CC(OC=4C=CC(OC)=CC=4)=CC=3)CCC2=CC=1OCCN1CCCCC1 DZEMPVYLCREZSC-UHFFFAOYSA-N 0.000 description 2
- CLSJOXWGAFSJKN-UHFFFAOYSA-N methyl 6-[2-(diethylamino)ethoxy]-2-[4-(4-fluorophenoxy)phenyl]sulfonyl-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C1CC2=CC(OCCN(CC)CC)=CC=C2C(C(=O)OC)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 CLSJOXWGAFSJKN-UHFFFAOYSA-N 0.000 description 2
- LSCSCGQQGGQAQO-UHFFFAOYSA-N methyl 6-[2-(diethylamino)ethoxy]-2-[4-(4-methoxyphenoxy)phenyl]sulfonyl-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C1CC2=CC(OCCN(CC)CC)=CC=C2C(C(=O)OC)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(OC)C=C1 LSCSCGQQGGQAQO-UHFFFAOYSA-N 0.000 description 2
- HXDVRGIRDFSOGY-UHFFFAOYSA-N methyl 6-hydroxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylate;hydrochloride Chemical compound Cl.OC1=CC=C2C(C(=O)OC)NCCC2=C1 HXDVRGIRDFSOGY-UHFFFAOYSA-N 0.000 description 2
- LHXOQONYXJOXES-UHFFFAOYSA-N methyl 6-hydroxy-2-[4-(4-methoxyphenoxy)phenyl]sulfonyl-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C1CC2=CC(O)=CC=C2C(C(=O)OC)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(OC)C=C1 LHXOQONYXJOXES-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 2
- JTWGJGBSDVIAKZ-UHFFFAOYSA-N n-[2-(2-hydroxyphenyl)ethyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCCC1=CC=CC=C1O JTWGJGBSDVIAKZ-UHFFFAOYSA-N 0.000 description 2
- DLVRAFDFBWHTGX-UHFFFAOYSA-N n-[2-(2-methoxyphenyl)ethyl]-4-methylbenzenesulfonamide Chemical compound COC1=CC=CC=C1CCNS(=O)(=O)C1=CC=C(C)C=C1 DLVRAFDFBWHTGX-UHFFFAOYSA-N 0.000 description 2
- JVEJTHKPLNDNOR-UHFFFAOYSA-N n-[2-(5-bromo-2-methoxyphenyl)ethyl]-4-(4-fluorophenoxy)benzenesulfonamide Chemical compound COC1=CC=C(Br)C=C1CCNS(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 JVEJTHKPLNDNOR-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- HMJKVTBQEACQST-UHFFFAOYSA-N n-hydroxy-2-[4-(4-methoxyphenoxy)phenyl]sulfonyl-6-(2-piperidin-1-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(S(=O)(=O)N2C(C3=CC=C(OCCN4CCCCC4)C=C3CC2)C(=O)NO)C=C1 HMJKVTBQEACQST-UHFFFAOYSA-N 0.000 description 2
- XKGUVNGZSZIHPH-UHFFFAOYSA-N n-hydroxy-6-(2-imidazol-1-ylethoxy)-2-[4-(4-methoxyphenoxy)phenyl]sulfonyl-3,4-dihydro-1h-isoquinoline-1-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(S(=O)(=O)N2C(C3=CC=C(OCCN4C=NC=C4)C=C3CC2)C(=O)NO)C=C1 XKGUVNGZSZIHPH-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000005981 pentynyl group Chemical group 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000007925 phenylethylamine derivatives Chemical class 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 1
- MIZLGWKEZAPEFJ-UHFFFAOYSA-N 1,1,2-trifluoroethene Chemical group FC=C(F)F MIZLGWKEZAPEFJ-UHFFFAOYSA-N 0.000 description 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
- 125000004510 1,3,4-oxadiazol-5-yl group Chemical group O1C=NN=C1* 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AODSTUBSNYVSSL-UHFFFAOYSA-N 1-fluoro-4-phenoxybenzene Chemical compound C1=CC(F)=CC=C1OC1=CC=CC=C1 AODSTUBSNYVSSL-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- JBUWGKPQQYRYCQ-UHFFFAOYSA-N 2-(5-bromo-2-methoxyphenyl)ethanamine;hydrochloride Chemical compound Cl.COC1=CC=C(Br)C=C1CCN JBUWGKPQQYRYCQ-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LDSQQXKSEFZAPE-UHFFFAOYSA-N 2-piperidin-4-ylethanol Chemical compound OCCC1CCNCC1 LDSQQXKSEFZAPE-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JKRSQNBRNIYETC-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-ol Chemical compound CN1CCN(CCCO)CC1 JKRSQNBRNIYETC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000018083 Bone metabolism disease Diseases 0.000 description 1
- 125000000172 C5-C10 aryl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010072970 Meniscus injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZXPJBQLFCRVBDR-UHFFFAOYSA-N acetic acid;methanesulfonic acid Chemical compound CC(O)=O.CS(O)(=O)=O ZXPJBQLFCRVBDR-UHFFFAOYSA-N 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005622 butynylene group Chemical group 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000005661 deetherification reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- XAAKCCMYRKZRAK-UHFFFAOYSA-N isoquinoline-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NC=CC2=C1 XAAKCCMYRKZRAK-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- MKLCLHOXQLPBTL-UHFFFAOYSA-N methyl 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-6-(2-morpholin-4-ylethoxy)-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C=1C=C2C(C(=O)OC)N(S(=O)(=O)C=3C=CC(OC=4C=CC(F)=CC=4)=CC=3)CCC2=CC=1OCCN1CCOCC1 MKLCLHOXQLPBTL-UHFFFAOYSA-N 0.000 description 1
- CSDDONFCHKCRDF-UHFFFAOYSA-N methyl 2-[4-(4-fluorophenoxy)phenyl]sulfonyl-6-hydroxy-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C1CC2=CC(O)=CC=C2C(C(=O)OC)N1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=C(F)C=C1 CSDDONFCHKCRDF-UHFFFAOYSA-N 0.000 description 1
- MSEKIQWICWQQJU-UHFFFAOYSA-N methyl 6-(2-imidazol-1-ylethoxy)-2-[4-(4-methoxyphenoxy)phenyl]sulfonyl-3,4-dihydro-1h-isoquinoline-1-carboxylate Chemical compound C=1C=C2C(C(=O)OC)N(S(=O)(=O)C=3C=CC(OC=4C=CC(OC)=CC=4)=CC=3)CCC2=CC=1OCCN1C=CN=C1 MSEKIQWICWQQJU-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- NLXXVSKHVGDQAT-UHFFFAOYSA-N o-(oxan-2-yl)hydroxylamine Chemical compound NOC1CCCCO1 NLXXVSKHVGDQAT-UHFFFAOYSA-N 0.000 description 1
- AEKHNNJSMVVESS-UHFFFAOYSA-N o-trimethylsilylhydroxylamine Chemical compound C[Si](C)(C)ON AEKHNNJSMVVESS-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000015590 smooth muscle cell migration Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- GASOCDUVJSYZGK-UHFFFAOYSA-N spirobenzofuran Natural products C1=2C=C(O)C(C)=CC=2OC(O)C21CC(=O)CC2(C)C GASOCDUVJSYZGK-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000034365 zymogen activation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005015040A DE102005015040A1 (de) | 2005-03-31 | 2005-03-31 | Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| PCT/EP2006/002440 WO2006102998A1 (de) | 2005-03-31 | 2006-03-17 | Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008534534A true JP2008534534A (ja) | 2008-08-28 |
| JP2008534534A5 JP2008534534A5 (enExample) | 2009-04-23 |
Family
ID=36571015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503400A Abandoned JP2008534534A (ja) | 2005-03-31 | 2006-03-17 | Ｍｍｐ阻害剤としての置換テトラヒドロイソキノリン、関連する製造法及び医薬としての使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7858619B2 (enExample) |
| EP (1) | EP1869001B1 (enExample) |
| JP (1) | JP2008534534A (enExample) |
| AT (1) | ATE495158T1 (enExample) |
| DE (2) | DE102005015040A1 (enExample) |
| WO (1) | WO2006102998A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210008493A (ko) * | 2018-05-09 | 2021-01-22 | 글루콕스 바이오테크 에이비 | 선택적인 nox 저해 활성을 가진 새로운 설폰아미드 유도체 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007113202A1 (en) | 2006-03-31 | 2007-10-11 | Glaxo Group Limited | Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists |
| JP2011506614A (ja) | 2007-12-17 | 2011-03-03 | ダイアックス コーポレーション | Ｍｍｐ−１４結合タンパク質を含む、骨溶解性障害を処置するための組成物および方法 |
| US8008445B2 (en) | 2008-03-03 | 2011-08-30 | Dyax Corp. | Metalloproteinase 9 binding proteins |
| JP2011517320A (ja) * | 2008-03-03 | 2011-06-02 | ダイアックス コーポレーション | メタロプロテアーゼ９結合タンパク質およびメタロプロテアーゼ２結合タンパク質 |
| US20110135573A1 (en) * | 2009-09-03 | 2011-06-09 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| AR080375A1 (es) | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida |
| US10314909B2 (en) | 2011-10-21 | 2019-06-11 | Dyax Corp. | Combination therapy comprising an MMP-14 binding protein |
| CN113980003B (zh) * | 2021-12-30 | 2022-05-20 | 北京鑫开元医药科技有限公司 | 一种2-((2-甲氧基苯基)磺酰基)异吲哚啉类化合物及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9611479B1 (pt) * | 1995-11-13 | 2009-01-13 | Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos. | |
| DE19719817A1 (de) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren |
| WO2003016248A2 (en) * | 2001-08-17 | 2003-02-27 | Bristol-Myers Squibb Company Patent Department | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
| DE10209299A1 (de) * | 2002-03-02 | 2003-09-18 | Aventis Pharma Gmbh | Cyclische N-substituierte alpha-Iminocarbonsäuren zur selektiven Inhibierung von Kollagenase |
| DE10300015A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen |
| DE10344936A1 (de) * | 2003-09-27 | 2005-04-21 | Aventis Pharma Gmbh | Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen |
| DE102004004974A1 (de) * | 2004-01-31 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen |
| DE102004031850A1 (de) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
-
2005
- 2005-03-31 DE DE102005015040A patent/DE102005015040A1/de not_active Withdrawn
-
2006
- 2006-03-17 EP EP06723484A patent/EP1869001B1/de not_active Not-in-force
- 2006-03-17 DE DE502006008710T patent/DE502006008710D1/de active Active
- 2006-03-17 JP JP2008503400A patent/JP2008534534A/ja not_active Abandoned
- 2006-03-17 WO PCT/EP2006/002440 patent/WO2006102998A1/de not_active Ceased
- 2006-03-17 AT AT06723484T patent/ATE495158T1/de active
-
2007
- 2007-09-27 US US11/862,818 patent/US7858619B2/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210008493A (ko) * | 2018-05-09 | 2021-01-22 | 글루콕스 바이오테크 에이비 | 선택적인 nox 저해 활성을 가진 새로운 설폰아미드 유도체 |
| JP2021523135A (ja) * | 2018-05-09 | 2021-09-02 | グルソックス・バイオテック・アーベー | 選択的なＮｏｘ阻害活性を有する新規のスルホンアミド誘導体 |
| JP7455762B2 (ja) | 2018-05-09 | 2024-03-26 | グルソックス・バイオテック・アーベー | 選択的なＮｏｘ阻害活性を有する新規のスルホンアミド誘導体 |
| KR102863909B1 (ko) * | 2018-05-09 | 2025-09-23 | 글루콕스 바이오테크 에이비 | 선택적인 nox 저해 활성을 가진 새로운 설폰아미드 유도체 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006102998A1 (de) | 2006-10-05 |
| US20080090821A1 (en) | 2008-04-17 |
| ATE495158T1 (de) | 2011-01-15 |
| DE502006008710D1 (de) | 2011-02-24 |
| US7858619B2 (en) | 2010-12-28 |
| EP1869001A1 (de) | 2007-12-26 |
| DE102005015040A1 (de) | 2006-10-05 |
| EP1869001B1 (de) | 2011-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2164914C2 (ru) | ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ | |
| FI106858B (fi) | Menetelmä terapeuttisesti käyttökelpoisen fenyyliamidiinijohdannaisen valmistamiseksi, joka sisältää 1-okso-2-isokinoliiniin perustuvan keskuksen | |
| US7157463B2 (en) | Substituted piperidines/piperazines as melanocortin receptor agonists | |
| US7291619B2 (en) | Melanocortin receptor agonists | |
| EP1009758B1 (en) | Meta-benzamidine derivatives as serine protease inhibitors | |
| US7858619B2 (en) | Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine | |
| CN102918034B (zh) | 多取代芳族化合物作为凝血酶的抑制剂 | |
| CZ289249B6 (cs) | Amidy a farmaceutické prostředky na jejich bázi | |
| EP1541563A1 (en) | Ccr4 antagonist and medicinal use thereof | |
| JP2003500383A (ja) | 第Ｘａ因子阻害剤 | |
| JP2003535844A (ja) | 第ＶＩＩａ因子阻害剤である（チオ）尿素誘導体、その製造方法およびその使用 | |
| RU2502736C2 (ru) | МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa | |
| JP2003514897A (ja) | ベータ−アミノ酸系、アスパラギン酸系およびジアミノプロピオン酸系Ｘａ因子阻害剤 | |
| JP2007501267A (ja) | 新規イミダゾール誘導体、その製造法及びその医薬としての使用 | |
| JPWO2003011812A1 (ja) | ヒト−β−トリプターゼ阻害活性を有する新規アミン誘導体およびそれを含有する医薬 | |
| US20070203118A1 (en) | Substituted tetrahydroisoquinolines used in the form of mmp inhibitors, method for the production and use thereof in the form of drugs | |
| IE64515B1 (en) | Tetrahydronaphthalene derivatives and preparation thereof | |
| RU2335494C2 (ru) | Производные бициклических иминокислот в качестве ингибиторов матриксных металлопротеиназ | |
| JP2002523486A (ja) | Ｎ−ヒドロキシアシルアミノ化合物、それらの製造方法、およびそれらを含む医薬組成物 | |
| JP2023506321A (ja) | 心臓病の治療のための心筋細胞増殖活性を有する複素環式誘導体の使用 | |
| SK283408B6 (sk) | Amidy a farmaceutické prostriedky na ich báze | |
| KR20070026662A (ko) | 4-트리플루오로메톡시페녹시벤졸-4'-설폰산, 이의 제조방법및 이의 의약적 용도 | |
| HK1105962A (en) | Substituted tetrahydroisochinolines used in the form of mmp inhibitors, method for the production and use thereof in the form of drags | |
| HK1117157B (en) | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090303 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090303 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20110111 |